// App-Quantinova.ai

: TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).

Researchers

Presenter

  • Ignacio Duran

Principal Investigators

  • Andrea Necchi

  • Thomas Powles

  • Yohann Loriot

  • Chethan Ramamurthy

  • Alejandro Recio-Boiles

  • Randy F. Sweis

  • Jens Bedke

  • Julia Tonelli

  • Mitch Sierecki

  • Petros Grivas

  • Philippe Barthelemy

Medical Centers

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • University of Arizona Cancer Center, Tucson, AZ

  • IRCCS Ospedale San Raffaele, Milan, Italy

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • University of Tuebingen, Tuebingen, Baden Wurttemberg, Germany

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Institut de Cancérologie Strasbourg Europe,Strasbourg, France, Strasbourg, France

  • Gilead Sciences, Inc, Morris Plains, NJ

  • University of Washington, WA

  • The University of Chicago Medical Center, Chicago, IL

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • Germany

  • Italy

  • France

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Creatinine

  • SRY-Box 10

Drug/Treatment

  • IMMU132

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT03547973

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved